If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


Mergers & Acquisitions

Lonza to sell specialties business for $4.7 billion to private equity firms

Sale to Bain and Cinven ends a long dalliance outside of health care and cements a move to pure-play

by Craig Bettenhausen
February 9, 2021

A computer mouse getting wiped with a wipe.
Credit: Shutterstock
The business Lonza is selling includes ingredients for wood preservation, agriculture, cleaning, and other markets.

Bain Capital and Cinven have struck a deal to buy Lonza’s specialty chemical business for $4.7 billion. The deal will move 17 manufacturing sites and 2,800 employees over to the private equity firms and allow Lonza to focus on its health-care business, including a 10-year deal to manufacture Moderna’s messenger RNA vaccine against COVID-19.

In 2020, when CEO Pierre-Alain Ruffieux announced Lonza’s intention to get out of specialty chemicals, the unit posted $1.9 billion in sales, 31% of Lonza’s total for the year. “This provides the [specialty chemical] business with a significant opportunity to find a home where its value can be fully appreciated and its potential can be unlocked,” Ruffieux wrote in the Swiss firm’s 2020 annual report.

The divestment is part of Lonza’s transition into a pure-play health-care company providing active pharmaceutical ingredients and other contract manufacturing services to the drug industry. It reverses a diversification move the company made in 2011 when it acquired the antimicrobial chemical maker Arch Chemicals for $1.4 billion. That deal made Lonza the largest supplier of pool-disinfectant chemicals and brought several related business lines.

Lonza took a first step toward undoing the diversification in 2018, when it sold the pool-chemical operations to the private equity firm Platinum Equity for $630 million. The sale to Bain and Cinven includes other former Arch operations as well as long-time Lonza businesses such as biocides, ketene chemicals, and resins for composites.

Sibylle Bischofberger Frick, a financial analyst who covers Lonza at Bank Vontobel, is optimistic about what the sale means for the firm. “They kept the strong growth units and they will grow fast, mainly in biologics, cell and gene therapy, and bioscience,” she says. “The remaining business is a pure contract development and manufacturing organization with good margins and interesting growth potential.”

Bischofberger expects Lonza to invest the proceeds of the sale in new plants and equipment, acquisitions, efficiency improvements, and R&D.



This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.